2005 JEFFERSON UROLOGY VISITING PROFESSOR
H. BARTON GROSSMAN, M.D.

The Department of Urology had the distinct pleasure of hosting Dr. H. Barton Grossman as the 2005 Visiting Professor (May 5-6, 2005). Dr. Grossman holds a dual/joint appointment Professor in the Department of Urology and Department of Cancer Biology at the University of Texas M. D. Anderson Cancer Center. He is director of Clinical Urology Research and the Bladder Cancer Multidisciplinary Program as well as Deputy Chairman, Department of Urology at M.D. Anderson Cancer Center, Houston, Texas. Dr. Grossman is internationally recognized as an expert in the areas of bladder cancer, and his primary research interest is in bladder cancer biomarkers for detection and prediction.

Dr. Grossman was delighted with his return visit to Philadelphia, since he is a native Philadelphian and was educated at La Salle University and Temple University School of Medicine. During his visit Dr. Grossman presented the following lectures: “An Overview: Superficial Bladder Cancer”, “Point of Care and Other Markers for Bladder Diagnosis”, “Cytologic Diagnosis of Transitional Cell Carcinoma of the Urinary Tract”, “Intravesical Therapy of Transitional Cell Carcinoma” and “Invasive Transitional Carcinoma—Surgical Therapy and Adjuvant Therapy”. All of these lectures were extremely informative and well received by the diverse audience of urologists, residents, students, and nurses.

Our urology residents from Jefferson had the opportunity to discuss several complex bladder cancer cases with Dr. Grossman. These discussions served as a very strong educational forum for the residents and students on the assessment and management of challenging bladder cancer cases. We are most grateful to Drs. Garlitz and Hubosky the urology chief residents who coordinated the itinerary and the residents for well prepared and organized case presentations.

A highlight to the program was 15 minute presentations representing pertinent clinical and basic science investigations in the area of bladder cancer by the Jefferson’s professorial staff. List of presentations with their representative departments included: “Cytologic Diagnosis of Transitional Cell Carcinoma of Urinary Tract” W. Klump, M.D. (Cytopathology), “New Targets for Gene Therapy in Bladder Cancer”, R. Baffa, M.D. (Urology); “Microsatellite Instability in Tumors of the Upper Urinary Tract”, T. Edmonston, M.D. (Pathology); “Regulation of Cell Growth and Migration in Bladder Cancer”, A. Morrione, Ph.D. (Urology); “Upper Urinary Tract Hereditary Experience with Non-polyposis Colorectal Cancer”, Dr. B. Boman, M.D., Ph.D. (Genetic and Preventive Medicine); “Hexyl Aminolevulinate Hydrochloride in Bladder Cancer”, I. Zeltser, M.D. (Urology); Upper Tract Transitional Cell Carcinoma Ablative and Topical Therapies”, R. Kuo, M.D. (Urology); and “Chemotherapy of Metastatic Transitional Cell Carcinoma”; A. Pereira-Rico, M.D. (Medicine). These presentations resulted in a stimulating brainstorming session with Dr. Grossman leading to innovative ideas for future investigations.

The Department of Urology expresses their gratitude to Pfizer for the sponsorship of the 2005 Jefferson Urology Visiting Professor.
Dear Colleagues,

This year marks our 101 year as a formal Academic Department. The Centennial celebrations of 2004 are behind us and we look to the future challenges and opportunities that our new academic year brings. Several faculty members have gone on to pursue other opportunities and fellows and chief residents alike are also starting new professional ventures and we wish them much success.

Our new academic year also brings changes in the structure of the Department. The continued external forces imposed on academic medicine in Philadelphia are well known. Significant reductions in reimbursements have negatively affected Urology practices across the US. These changes have hit the Philadelphia marketplace and our department particularly hard. Difficult decisions had to be made with support staff reductions in Urology and other Jefferson Clinical Departments. We are sad to see these colleagues leave our Department due to budgetary layoffs.

On a positive note as we move forward, we have new faculty joining our Department with Drs. Koppel and Lallas arriving this summer. Our lab research team recently was awarded a 1.1 million dollar NIH grant and the hospital has finally committed to purchase a DaVinci robot for laparoscopic procedures. These changes will make our Department a strong one in spite of the changing times. I would like to thank everyone for their support as the new academic year begins and look forward to our team continuing to make our Department one of the “destinations” for urologic care and education in the region.

Leonard G. Gomella, M.D.

CLINICAL TRIAL HIGHLIGHTS

**Title:** A Phase 1, Randomized, Placebo-Controlled, Crossover, Target Validation Study of CP-122,721 In Subjects with Neurogenic Detrusor Overactivity.

**Principal Investigators:** Patrick J. Shenot, M.D.

**Sponsor:** Pfizer, Inc.

The Department of Urology is currently conducting a research study on a new investigational medication, CP-122,721, for overactive bladder (OAB) in men and women with multiple sclerosis (MS).

Overactive bladder is a chronic and debilitating condition that is characterized by hyperactivity of the bladder resulting in symptoms of urinary urgency, urine leakage, with increased frequency of daytime and nighttime voiding. This condition has a negative impact on the quality of life of sufferers, enhancing the medical need for new pharmaceutical therapies.

Multiple Sclerosis is a disease that affects the brain and spinal cord resulting in loss of muscle control. This loss of muscle control includes the loss of bladder function and the onset of OAB symptoms. OAB may be explained as hyperactivation of bladder receptors as a result of neurogenic input. Modulation of the bladder receptors activity and/or sacral reflex for controlling involuntary detrusor contraction is an approach to OAB treatment. Substance P, through neurokinin -1 (NK-1) receptors, mediates the micturition reflex. Preclinical evidence suggests that substance P antagonists may have therapeutic value in detrusor overactivity. This study is designed to evaluate the effect of CP-122,721, a selective NK-1 receptor antagonist in subjects with neurogenic OAB related to multiple sclerosis.

The objectives of this study are to evaluate the preliminary efficacy of 3-week treatment of CP-122,721, a NK-1 antagonist, in subjects with neurogenic detrusor overactivity in a target validation study and to evaluate the safety and tolerability of 3-week treatment CP-122,721 in subjects with neurogenic detrusor overactivity.

In this study eligible subjects will be determined during a screening visit. Only eligible subjects will be randomized to receive either oral CP-122,721 capsule (100mg) or matching placebo twice daily for 3weeks (Treatment Period 1). At the end of Treatment Period 1, there will be 2-3 week washout phase. In Treatment 2, subjects will receive the treatment that they did not receive during Treatment Period 1 for 3weeks. A follow-up evaluation will be performed 7-10 days after completion of Treatment Period 2.

During Treatment Periods 1 and 2, blood serum analysis will be monitored weekly if any adverse abnormalities should arise. Subjects with clinically significant abnormal test results will be discontinued with study medication.

Standard urodynamic studies will be performed at screening, the end of Treatment Period 1, and the end of Treatment Period 2. Symptom severity of detrusor overactivity will be evaluated using the OAB-q symptoms Bother Items at the same time-points. Each subject will also be required to complete a 3-day micturition diary at screening and at the end of each treatment period.

**Inclusion criteria.** Male or female, between 18 and 65 years of age, inclusive; who has given written informed consent. The study patients must have multiple sclerosis, with mild degree of disability (Kurtzke EDSS <6). Other requirements include: Body Mass Index between approximately 18 to 35 kg/m²; total body weight > 50kg (110 lbs); test confirmed to be Extensive Metabolizers by CYPD2D6 genotyping; must be willing and able to return to the clinical research unit as required by the protocol, and able and willing to complete a micturition diary correctly and independently.

**Exclusion criteria.** Subjects will be excluded if they exhibit a poor metabolizer genotype those who are taking interferon-β. Subjects must be off medications with significant anticholinergic effects for at least 2 weeks before screening urodynamic evaluation and before randomization. Subjects who are taking and cannot safely discontinue medications which can inhibit CP-122,721in any possible way. Subjects with the following conditions or who have had the following procedures will be excluded from this trial: 1) detrusor overactivity attributable to other neurogenic etiologies, such as diabetes mellitus or spinal cord injury; 2) History of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric or allergies disease except for stable medical conditions associated with MS and/or detrusor overactivity, 4) history of significant urinary outlet obstruction, 5) urogenital surgery (prostatectomy, hysterectomy, prolapse and incontinence surgery ) and/or local pathology such as marked cystocele, pelvic prolapse, urinary tract infection, bladder stones or unexplained hematuria < 6 months prior to screening 6) use of indwelling catheter and intermittent self-catheterization < 6 months prior to screening, 7) pregnant or breast-feeding women; women of childbearing potential who are unwilling or unable to use an acceptable method of contraception 8) Consumption of grapefruit or grapefruit containing products within 14 days prior to first dose of study medication.
FAREWELL to 2004-2005-CHIEF RESIDENTS AND FELLOWS

Our Department congratulates Scott G. Hubosky, M.D., and Cristopher J. Garlitz, M.D., upon their completion of the TJUH Surgery Resident Program in Urology.

Cristopher J. Garlitz came to Jefferson Medical College 10 years ago following undergraduate studies at Notre Dame University. Cris graduated *cum laude* from Jefferson Medical College and stay on for his residency training in urology. Cris and Susan, his fiancée, will venture to Seattle, Washington, where he will continue his endeavors in Laparoscopy Robotics Fellowship at the University of Washington Medical Center. Cris is grateful to many individuals who made his experience here extraordinary, especially his fellow residents, attendings, and the OR and office staff.

Scott G. Hubosky, a Pennsylvania native was born in Hazleton and raised in Phoenixville. Scott received a B.A. from Franklin & Marshall College and graduated *cum laude* from Loyola University Stritch School of Medicine, Maywood, Illinois. His future plans include his wife Amy and daughter Deven with a Laparoscopy/Endourology Fellowship at Eastern Virginia Medical School, Norfolk, Virginia. Scott would like to thank his fellow residents for their daily friendship, advice, and hard work, as well as the attendings who are the foundation of the learning experience here at Jefferson.

Pankaj Kalra, M.D. completed his urology residency at the University of Illinois. On completion of his residency training, Pankaj has been the C.R. Bard/Bagley Endourology and Laparoscopic Fellow for 2004-2005 at Thomas Jefferson University Hospital. He now plans on settling in the Philadelphia area with his wife, Suleena and his daughter, Shreya. He will be applying the minimally invasive surgical techniques obtained from his fellowship at Tri-County Urological Associates, Pottstown, Pennsylvania. Pankaj is most appreciative to the faculty and residents at the Jefferson Department of Urology for making his fellowship both a valuable and enjoyable experience.

Michael R. Lee, D.O. completed both his general surgical preliminary and urologic surgery residency training at Albert Einstein in Philadelphia, PA. Mike has spent this past year at Thomas Jefferson Medical College as a Clinical Instructor and Urologic Oncology Fellow under the mentorship of Dr. Leonard Gomella. In July, Mike and his wife, Rachel and his children, Kyra and Aiden will be traveling to Fort Collins, Colorado where Mike will be joining a private practice group. Mike looks forward to bringing cryoablation, laparoscopy, and robotic urologic surgery to Northern Colorado. Mike is thankful for the incredibly talented Jefferson Urology Residents. He would also like to express his deepest gratitude to Drs. Gomella, Glassman, and Trabulsi for providing him with “hands down, the best year of his training.

Jefferson Urology Associates
Philadelphia
Philadelphia Magazine
May 2005

Demetrios H. Bagley, M.D. and Leonard G. Gomella, M.D. were noted as “Top Docs” in the May 2005 edition of Philadelphia Magazine. Dr. Bagley was acknowledged for his expertise in endourology, kidney and ureteral stones and Dr. Gomella for urologic oncology.
DEPARTMENT OF UROLOGY AWARDED $1.1 MILLION NIH GRANT FOR BLADDER CANCER STUDY

Andrea Morrione, PhD, Research Assistant Professor in the Department of Urology has received a five-year $1.1 million grant from the National Institutes for Health (NIH) for a study aimed at improving prognosis and therapy in bladder cancer. Raffaele Baffa, MD, Associate Professor of Urology is co-principal investigator on the project.

The study, entitled “Proepithelin Signaling in Urothelial Cells,” will investigate the role that the growth factor proepithelin plays in transformation of bladder cancer cells using cell culture models and bladder cancer samples.

The study’s significance, says Dr. Morrione, “is not only in terms of a better knowledge of proepithelin action in the biology of bladder cells, but in the longer range this study could yield valuable information for translational research.”

“This successful grant application was made possible through the University’s Tobacco Settlement funds, showing that this innovative new program can be successful in expanding research in key areas such as bladder cancer,” said Leonard G. Gomella, MD, Chair of Urology and Bernard W. Godwin Jr. Professor for Urology, Jefferson Medical College. The grant was awarded by the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

BLADDER CANCER RESEARCH IN UROLOGY

The Role of Proepithelin in Bladder Cancer - Andrea Morrione, PhD

Although Bladder cancer is the 5th most common cancer in the United States, very little is still known about the molecular mechanisms that determine tumor formation in the bladder urothelium. Most bladder cancers arise in the bladder epithelium and regardless of treatment with surgery, chemotherapy or immunotherapy, they often recur and/or metastasize. In our laboratory we are currently investigating the role of the growth factor proepithelin in bladder cancer.

The growth factor proepithelin (also known as progranulin, acrogranin, PC-derived growth factor or granulin-epithelin precursor) is a secreted glycoprotein that functions as an important regulator of cell growth, migration and transformation in several cancer models. Proepithelin is over-expressed in a great variety of cancer cell lines and clinical specimens of breast, ovarian and renal cancer, as well as glioblastomas.

We have recently investigated the effects of proepithelin on urothelial cells using conditioned medium from proepithelin-overexpressing fibroblasts or human purified recombinant proepithelin and shown that proepithelin promotes migration of normal and transformed urothelial cells and stimulate in vitro wound closure and invasion. These effects required the activation of the mitogen-activated protein kinase pathway.

The ability of cancer cells to migrate and invade through extracellular matrix is a critical step for tumor metastasis to occur. Our results suggest that proepithelin by promoting the migration and invasion of bladder cancer cells may determine the transition from a non-invasive to an invasive phenotype in bladder cancers and perhaps in other solid tumors, where the role of proepithelin in promoting invasion and migration has been reported as well. Cell migration is also a fundamental aspect in numerous normal processes. Proepithelin expression is detectable in normal bladder urothelium and promotes migration of primary cultures of normal urothelial cells. Thus, our results would strongly suggest that proepithelin is not only important for migration of bladder cancer cells but may also play a physiological role in regulating cell migration of normal urothelial cells.

In conclusion, the identification of proepithelin as a novel regulator of tumor cell motility and invasion could represent an additional molecular target for bladder cancer and could provide new leads for developing novel tumor markers and for improved therapeutic approaches against bladder cancer.
THE DIVISION OF UROLOGY AT ALFRED I. DUPONT HOSPITAL

The Department of Urology at Thomas Jefferson University would like to highlight our “Pediatric Urology Affiliate” at Alfred I. DuPont Hospital for Children/Nemours Children’s Clinics.

The Division of Urology is staffed by a team of specially-trained pediatric urologists: T. Ernesto Figueroa, M.D., Chief of Urology, Julia Spencer Barthold, M.D., Associate Chief of Urology, and Ricardo Gonzalez, M.D. Director of the Bladder Clinic. Dr. Paul Noh, Jefferson Medical College, Class of 1998, will join the faculty in July, 2005. These pediatric urologists evaluate and treat conditions such as hydronephrosis, kidney stones, urinary tract infections, vesicoureteral reflux, urinary tract obstruction, and neurogenic bladder. This Division also treats genital abnormalities such as hypospadias, undescended testes, phimosis, and hydrocele.

Since the first laparoscopic procedure performed by their team in 1994, they have greatly expanded the scope of the conditions that can be successfully managed laparoscopically- including pyeloplasties, partial and total nephrectomies, repair of varicoceles, orchiopexies and orchiectomies, ureteral reimplantation, and laparoscopic-assisted bladder augmentation. With the use of miniaturized laparoscopic instruments many of these procedures have been performed in infants.

In addition, over the last decade, these pediatric urologists have expanded their methods to deal with urinary calculi to include the use of the Holmium laser and extracorporeal shock wave lithotripsy.

The Division of Urology also offers a complete service for the evaluation and management of urinary incontinence in children, including daytime voiding disorders, and state-of-the-art surgical correction of complex anatomical causes of urinary incontinence. In order to address the growing need for the management of these conditions, a specialized Bladder Clinic was developed, where children with voiding disorders can be evaluated and treated by their staff dedicated to this effort.

Of particular note, Dr. Ricardo Gonzalez, an internationally renowned surgeon, brings a very unique skill set to the care and treatment of children requiring reconstructive urology. Dr. Julia Barthold has received an NIH grant award to Nemours for her clinical research studies in the area of the undescended testis.

From the simplest to the most complex conditions, these pediatric urologists are there for the children. Their offices include the following locations: Alfred I. DuPont Hospital for Children/Nemours Children’s Clinics (302-651-5980, -5986), Jefferson/DuPont Children’s Health Program (215-955-6892), and Bryn Mawr/DuPont Children’s Health Program (610-581-7570).

T. Ernesto Figueroa, M.D., Chief, Division of Urology, is a graduate of Tulane University in New Orleans, where he also completed his residency in Urology. He served his fellowship in pediatric Urology at Children’s Hospital of Michigan. Dr. Figueroa is certified by the American Board of Urology. His clinical interests are neurogenic bladder, undescended testes, hypospadias, congenital genital anomalies, vesicoureteral reflux, and urinary tract infections and voiding disorders in childhood. Dr. Figueroa is a Clinical Associate Professor of Urology at Thomas Jefferson University.

Julia Spencer Barthold, M.D., Associate Chief and Director of Research, Division of Urology, is a graduate of Northwestern University, Chicago, IL, where she also completed her residency in Urology. She completed a fellowship in pediatric Urology at Children’s Hospital of Michigan and at the Foundation for Urologic Disease Research Scholar at Cornell University Medical College. Dr. Barthold is certified by the American Board of Urology. Her clinical interests are cryptorchidism, genital anomalies, and genitourinary tract reconstruction. Dr. Barthold is an Associate Professor of Urology at Thomas Jefferson University.

Ricardo Gonzalez, M.D., Director of Pediatric Urology Fellowship Program, Director of Bladder Clinic, is a graduate of Facultad de Medicina, University of Buenos Aires, Argentina. He completed his residency in general surgery at Hospital Militar Central, Buenos Aires, and served a fellowship in urologic surgery at the University of Minnesota. Dr. Gonzalez is certified by the American Board of Urology. His clinical interests are complex urogenital reconstruction, fetal urological surgery, neurogenic bladder and myelomeningocele, artificial urinary sphincter, and laparoscopic surgery. Dr. Gonzalez is recipient of the European Society for Pediatric Urology’s Medal of Honor, which recognized his outstanding contributions at the international level in the field of pediatric urology. Dr. Gonzalez is a Professor of Urology at Thomas Jefferson University.
ALUMNI RESIDENT AND FELLOW KORNER
STUART LIBERMAN, M.D. – RESIDENCY

After leaving Jefferson in 1996, Stuart Liberman, M.D. joined a large multi-specialty group in Melbourne, Florida. They have over 100 physicians and 4 urologists in the group, with offices throughout Brevard County. Stu has a thriving general urology practice and serves on the Neoplastic Disease Committee at Holmes Regional Medical Center. In addition, he has been an investigator on several pharmaceutical studies, including a phase II trial of Interferon alpha 2b and BCG for treatment of superficial bladder cancer as well as the REDUCE study.

Dr. Liberman and his family live in Melbourne, which is an oceanfront community located on the East coast of Central Florida, near Cape Canaveral. His wife Lisa is an avid tennis player and involved in numerous fund raising activities. Their sons Joshua (almost 12) and Jacob (7 ½) love the availability of year round outdoor activities such as boating, fishing, swimming and surfing. Stu spends his free time racking up the miles on his road and mountain bike.

“The Liberman Family
Lisa, Jacob, Stu, and Joshua

We are most grateful to Stu Liberman for sharing his life happenings since his residency at Jeff. We are randomly selecting residents from our alumni and will highlight that resident to their whereabouts, urological interests, and family updates.

“JUP’S GUIDING STAR” HIGHLIGHTS
UROLOGY’S CLINICAL PRACTICE EMPLOYEES”

Doreen Conway received “The Spotlight on Service Excellence Award for May”. JUP’S Guiding Star stated, “Doreen’s nomination was based on a letter received from the Chairman of another department who was impressed by Doreen’s actions during his visit to the office. Doreen received a Certificate of Award, a JUP lapel pin and a $50 American Express Gift Check.

An Honorable mention was given to Linda Rondinelli of Urology, who was also nominated. Linda received a Certificate of Appreciation.” It is an honor to have both Doreen and Linda as part of our urology staff. Their work attitude has provided our patients with a pleasant and positive experience.

The Department of Urology is most grateful to them.

BARBARA B. FRANK, M.D. AS GE CLINICAL EDUCATOR of 2005

Dr. Barbara B. Frank, wife of Leonard A. Frank, M.D. has been awarded 2005 Outstanding Clinical Educator by The American Society for Gastrointestinal Endoscopy. She has served as a clinical Professor of Medicine in the Division of Gastroenterology and Hepatology at Hahnemann/MCP/Drexel University College of Medicine since 1973. Dr. Frank has chaired and served on numerous national (Gastroenterology Drug Advisory Committee of the U.S. Food and Drug Administration, FDAs Gastroenterology-Urology Devices Panel, Governor for PA of the American College of Gastroenterology, Representative to PA Medicare Carrier Advisory Committee) and local (Philadelphia Gastrointestinal Training Group, the Delaware Valley Society for Gastrointestinal Endoscopy) committees in gastroenterology. She was the first women to be named “Physician of the Year” by the Philadelphia Chapter of the Crohn’s and Colitis Foundation of America. Her recognition as a leader in women’s issues cannot be overstated.

Drexel University College of Medicine has newly established The Barbara B. Frank, M.D. Endoscopic Learning Resource Center. It will become a nationally-recognized center for teaching novel endoscopic techniques and developing new endoscopic technologies. The center will provide a resource to residents, fellows and physicians in the Tri-state area to learn the latest technologies for endoscopic diagnosis and treatment. This center is a true tribute to Barbara Frank whose dedication to the field of Gastrointestinal Endoscopy has reached so many and will continue to do so throughout the future.

The Department of Urology at Thomas Jefferson University expresses congratulations to Barbara Frank, M.D.
FAREWELL to
Cristopher J. Garlitz, M.D.
Scott G. Hubosky, M.D.
Joanna K. Chon, M.D.
Ramsay L. Kuo, M.D.
Michael R. Lee, M.D.
Pankaj Kalra, M.D.
Your friends and coworkers will always be wishing the best for you.
PATRICK J. SHENOT, MD - UROLOGY’S VICE CHAIRMAN ACADEMIC AFFAIRS

Dr. Leonard G. Gomella is pleased to announce P.J. Shenot as the Vice Chairman for Academic Affairs in the Department of Urology. Dr. Gomella noted, “Dr. Shenot’s involvement with graduate medical education has been apparent over the last several years. This appointment will allow him to become more actively involved at higher levels with directing the future of the training of both our residents as well as our students. Everyone knows that Dr. Shenot has been an untiring advocate for the residents over the years. His training at Jefferson in both his residency and Neurourology Fellowship, has given him a unique perspective on the intricate operations of the medical center.

DAVINCI ROBOTIC SYSTEM COMES OUR WAY

Dr. Leonard Gomella announced that the Da Vinci Robotic System has been incorporated into the 2006 capital budget. Dr. Gomella stated, “This has been an area of great concern to many members of our department, as well as members of the Cancer Center and our Junior Faculty. The addition of this important piece of equipment will do much to allow us to maintain our leadership in urologic laparoscopic interventions.” Dr. L. Gomella would like to thank everyone and in particular, Tom Lewis and Alan Brechbill, and the TJU Hospital Board for their significant support of this major purchase. The Department of Urology is looking forward to setting up a working group with Dr. Diehl and members of the operating room staff to discuss the strategy to begin this program in the best interest of all parties.

<table>
<thead>
<tr>
<th>Date</th>
<th>Speaker</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 5</td>
<td>P.J. Shenot</td>
<td>Invited Speaker, Grand Rounds- Department of Rehabilitation at TJUH,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lecture: “Classification and Diagnosis of Neurogenic Bladder”, PA</td>
</tr>
<tr>
<td>April 9</td>
<td>P.J. Shenot</td>
<td>Invited Speaker, Grand Rounds- Department of Rehabilitation at TJUH,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lecture: “Management Neurogenic Bladder”, PA</td>
</tr>
<tr>
<td>April 16</td>
<td>L.G. Gomella</td>
<td>Speaker, Presenter for Philadelphia College of Osteopathic Medicine-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Continuing Medical Education: Current Status in the Diagnosis and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment of Prostate Cancer, Lecture: “Controversies in...”</td>
</tr>
<tr>
<td>April 20</td>
<td>L.G. Gomella</td>
<td>Speaker, Grand Rounds- Moses Taylor Hospital, Lecture: Practical</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Approaches to Prostate Cancer”, Scranton, PA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Speaker, Community Cancer Center Program- - Moses Taylor Hospital,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lecture: What Every Man and Women Should Know About Prostate Cancer”,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Scranton, PA</td>
</tr>
<tr>
<td>April 21</td>
<td>R. Kuo</td>
<td>Faculty, Society of Engineering and Urology, Lecture: “Digital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Communications in OR and Clinical Settings”, San Antonio, Texas</td>
</tr>
<tr>
<td>June 10-11</td>
<td>L.G. Gomella</td>
<td>Course Director, Perspectives in Men’s Health “Straight To The Point”,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Washington, DC</td>
</tr>
<tr>
<td>June 16</td>
<td>L.G. Gomella</td>
<td>Speaker, Long Island Jewish Medical Center, Albert Einstein College</td>
</tr>
<tr>
<td></td>
<td></td>
<td>of Medicine, “Research Year in Review”, Participant in Round Table”,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Long Island, NY</td>
</tr>
</tbody>
</table>

JUN Newsletter published by
Jefferson Urology News,
1025 Walnut Street, Philadelphia, PA 19107
Phone #  215-955-1706

Editors: Denise Tropea and Dolores Byrne
JUN News thanks the following Contributors:
T.E. Figueroa, L. Gomella, A. Morrione, D. Byrne and D. Tropea

In Memoriam
George H. Strong, M.D.
1914 - 2005